New detection method for protein degraders
German researchers have developed a new way to detect the about 300 cullin-RING ligases (CRLs) which specifically trigger destruction of specific proteins in the cell.
??Study: New breeding methods hardly contribute to climate protection
According to Swiss bioethicists, deregulation of genetic engineering rules for plants optimised through targeted mutation and cisgenetics will make little contribution to climate protection by 2050.
CEPI commits up to US$80m to University of Oxford to develop vaccines
The Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Oxford have entered into a strategic partnership to accelerate the development of globally accessible vaccines against endemic outbreaks.
Pairwise and Bayer collaborate to CRISPR short-stem maize
Bayer and Pairwise extend their collaboration in precision breeding for five further years to develop CRISPR applications for Bayer’s Preceon Smart Corn System.
Mystery solved: Mysthera Theapeutics launches with $3.5m
Mysthera Therapeutics AG has launched in Basel with $3.5m in seed funding from founding investor Forty51 Ventures. The capital will be used to advance its preclinical portfolio in a variety of autoimmune indications. The focus is on pan-PIM kinase inhibitors that uniquely modulate multilineage immune cell functions.
Mithra raises 20m through private placement
Women’s health specialist Mithra Pharmaceuticals SA has entered into a definitive agreement to raise 20m in gross proceeds via a private placement of 10 million new ordinary shares with Armistice Capital.
Synbio experts develop cells that hear
ETH Zurich researchers have developed a gene switch that triggers insulin release in designer cells by playing music.
Researchers decipher mystery of oil-eating microbes
Oil-eating bacteria form dendritic biofilms that reshape oil droplets to speed up the rate of consumption
Valneva announces extension of existing loan agreement
French vaccine maker Valneva SE will double the amount of a US$100m debt financing granted by Deerfield Management Company and OrbiMed.
Spexis AG bags money for pivotal Phase III trial
Swiss Spexis AG has announced a US$2.5m capital commitment to fund a two-part pivotal Phase III study to get market approval for its inhaled cystic fibrosis antibiotic colistimethate sodium.